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A B S T R A C T
Background: Multiple Sclerosis (MS) clinical trials increasingly focus on progressive and advanced MS, with
upper limb function (ULF) as a key outcome. Within clinical trials, Patient Reported Outcomes (PROs) quantify
clinical variables and establish meaningfulness of changes. Scientific standards and regulatory criteria (from
Food and Drug Administration [FDA]) require PROs be “fit-for-purpose”: well-defined and reliable measures of
specific concepts in defined contexts.
Objective: To identify, from literature, existing PROs measuring ULF and determine which satisfy scientific and
regulatory clinical trials requirements.
Method: We screened PubMed/Web of Science using multiple relevant terms. Abstracts and full texts were
screened using suitability criteria. PRO development papers were evaluated using recently expanded Consensus
Standards for Measurement Instruments (COSMIN) criteria for content development.
Results: We identified 3619 articles; 485 used 24 different ULF PROs. No PRO satisfied scientific and regulatory
requirements as a well-defined measure of a clearly defined construct in a specific clinical context.
Conclusions: Existing ULF PROs don't meet fit-for-purpose criteria. MS clinical trials require new measures with
greater emphasis on patient engagement to derive theoretical frameworks, concepts of interest, and contexts of
use followed by systematic literature searches, expert input, and qualitative research to support item generation.
Until then, trials will miss aspects of meaningful within-patient change and thereby misrepresent (likely un-
derestimating) treatment effects.
1. Background
Clinical trials for people with progressive and advanced multiple
sclerosis (MS) have steadily increased over the past decade [1–3]. This
represents evidence that MS pathology might be influenced throughout
the disease course and the importance of protecting individuals upper
limb function (ULF). However, these MS context present measurement
challenges. The widely-used EDSS (Expanded Disability Status Scale)
[1] quantifies overall function, but does not delineate ULF [2]. The nine
hole peg test (9-HPT) (used stand-alone or in the MS functional com-
posite (MSFC)), has valuable measurement properties. Whilst it is an
“objective” timed hand function performance test (albeit under sub-
jective control) with equal interval units (seconds), the 9-HPT doesn't
measure peoples' ability to perform routine tasks in daily life. Instead,
patient-reported outcomes (PROs) are required.
PRO requirements have developed over the last decade. A key de-
velopment is measurement clarity: PROs must measure clearly defined
concepts in specific clinical contexts. The US Food and Drug
Administration (FDA) have been instrumental from a regulatory per-
spective [5,11] – although these are long held measurement science
views from some quarters [3].
The fundamental logical requirement is content validity – the extent
to which PRO content adequately reflects the measurement construct
[4]. The FDA advise that this is achieved using an iterative process of
qualitative and quantitative approaches (See Box 1). Content validity is
cited the most important measurement property of a PRO [5], and ac-
cording to FDA guidance, these basic requirements of content validity
should be established prior to any statistical (i.e. psychometric”) ex-
amination.
Here, we review existing ULF PROs against content validity criteria
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to inform PRO selections for MS clinical trials, and identify future ad-
vancements to satisfy scientific and regulatory criteria. We used
Consensus Standards for Measurement Instruments (COSMIN's) check-
list and quality indicators [5], which have been updated to incorporate
content validity assessments that align with FDA guidance (Box 1).
2. Methods
2.1. Objective
To identify, from literature, existing ULF PROs and determine which
meet regulatory and scientific requirements as fit for purpose in MS
clinical trials, using expanded COSMIN standards for content develop-
ment. As many scales are re-validated or adapted for use in other
clinical contexts (i.e. beyond the original context of interest), we did
not restrict our literature searches to MS, but instead utilized an in-
clusive search strategy to identify any PROs for ULF. This approach
would enable us to identify any ULF PROs that may be suitable for
future deployment or validation in an MS context of interest. Any re-
sulting ULF PROs were assessed using the COSMIN checklist for PRO
content development – which maps onto FDA criteria (Box 1) – and in
this manner, we would determine if any PROs meet regulatory criteria
for MS clinical trials.
2.2. Literature review
We searched electronic databases (PubMed, Web of Science) for all
articles published prior to November 30th 2017. Search terms were a
combination of keywords relating to the concept of ULF [upper ex-
tremity, arm, dexterity, motor control, hand control, hand activity] and
PROs [scale, instrument, patient reported outcome, questionnaire]. The
search was not exclusive to MS, but restricted to articles on human
subjects and English language.
Abstracts of returned articles were screened by two independent
(blinded) reviewers to identify papers discussing ULF PROs. These were
reviewed at full text level to identify cited PROs. During full-text
screening, articles were excluded if the instrument was not a PRO, not
measuring ULF, developed for children, the PRO or development paper
was not accessible (see Fig. 1 for flow diagram).
2.3. Quality analysis
For all PROs meeting inclusion criteria, we assessed the original
development paper for the extent to which the PRO met requirements
for instrument content development. Historically, established standards
for PRO evaluation, such as COSMIN and EMPRO (Evaluating the
Measurement of Patient-Reported Outcomes) [6–8], have focused pri-
marily on psychometric properties, and have only covered limited as-
pects of conceptual development. However, COSMIN standards were
recently extended to include comprehensive assessment of content de-
velopment [5,9].
According to COSMIN guidelines, PRO reviews (such as this paper)
should clearly define their scope, including “the construct, target po-
pulation, and context of use”. This provides the frame of reference for
evaluating content validity [9]. Here, we assessed ULF PROs in the
context of clinical trials, and more specifically MS treatment trials.
Aligning with COSMIN, scientific and regulatory requirements and re-
commendations detailed in Box 1, we targeted the revised COSMIN
checklist items associated with PRO content. Other reviews of PRO
content development have employed this strategy [10,11]. We focused
on the first section of COSMIN's checklist which maps directly to FDA
guidance, comprising “Box1a”, items 1–6 [6]; see Box 1.
Aligning our methods to recent publications applying these new
standards (11), one reviewer (JC) extracted data from studies. A second
reviewer (JH) double-checked accuracy of 20% of extracted informa-
tion. The extracted information was next assessed on a 4-point scale;
Box 1
Summary of FDA guidance for establishing content validity of PROs for clinical trials (left) and corresponding COSMIN checklist items (right).
FDA guidance Corresponding COSMIN items (Box 1a of revised guidelines)
Concept of interest. The Concept of Interest (COI) should measure a meaningful treatment
benefit of symptoms or function. If no PRO instruments exist to assess the COI, new
PRO instruments should be developed (or adapted from existing instruments).
Item 1: Is a clear description provided of the construct to be measured?
Conceptual framework. Content validity is underpinned by a conceptual framework. Ac-
cording to the FDA documentation, “one fundamental consideration in the review of a
PRO instrument is the adequacy of the item generation process to support the final conc-
eptual framework of the instrument.” An iterative process of development should be
followed. This includes hypothesizing an initial conceptual framework before draft-
ing new instrument on the basis of literature review, expert review and qualitative
research in the targeted patient population. In most instances, the final model will
describe the COI as domains and subdomains, along with their hypothesized relati-
onships.
Item 2: Is the origin of the construct clear: was a theory, conceptual framework or
disease model used or clear rationale provided to define the construct to be measured?
Context of use. The context of use (COU) specifically defines the target population for the
COI (e.g. clinical group/subgroup, sex, age, ethnicity) and the intended context (e.g.
clinical, rehabilitation, trials).
Item 3: Is a clear description provided of the target population for which the PROM
was developed?
Item 4: Is a clear description provided of the context of use?
Item identification and development. Items should be identified via both [1] literature re-
views and [2] qualitative work, with iterative cycles of patient/expert input to adjust
both the theoretical framework and items, thus ensuring content validity. In partic-
ular, input from the target population (i.e. the COU) should be documented from
focus groups or interviews to evaluate items, wording and coverage. According to the
FDA, “Sponsors should provide documented evidence of patient input during instrument
development and of the instrument's performance in the specific application in which it is
used (i.e., population, condition)… Without adequate documentation of patient input, a
PRO instrument's content validity is likely to be questioned.”
Item 5: Was the PROM development study performed in a sample representing the
target population for which the PROM was developed?
Item 6: Was an appropriate qualitative data collection method used to identify
relevant items for a new PROM?
Finally, we added a further item to the checklist (derived from FDA criteria):
Item 6a: were appropriate literature searches conducted to identify relevant items for
a new PROM?
Item reduction and finalisation of instrument. The processes by which an instrument was
finalised should be well documented, including the reasons for deleting or modifying
items (e.g. via qualitative or statistical approaches).
Not covered by COSMIN standards.
Appropriate documentation. Before a measure is suitable for deployment in a clinical trials,
appropriate documentation should be in place. This should include a published de-
velopment history; a user manual with guidelines for study interpretation and scoring
of measure.
Not covered by COSMIN standards.
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“good’ (+), “adequate” (+?), “doubtful” (−?), “poor/none” (−), ac-
cording to the process specified in the COSMIN documentation,
‘COSMIN methodology for assessing the content validity of PROMs User
manual version 1.0’.1 Whilst scoring in COSMIN checklist is item spe-
cific, assessment ranges from ‘good’ (i.e. a widely recognised approach)
to ‘poor/none’ (i.e. approach not documented or missing). Whilst some
subjectivity is unavoidable – especially in the middle of the scale – both
reviewers independently assessed each item on the checklist, with any
inconsistences resolved verbally.
3. Results
Literature searches identified 3610 articles (Fig. 1), with a further 9
articles identified from papers' reference lists. Abstract screening ex-
cluded 3001 articles not related to ULF or PROs, and 133 were excluded
according to other criteria (see methods and Fig. 1). The remaining 485
articles contained 24 unique ULF PROs.
3.1. PRO descriptions
Table 1 shows descriptive information of the 24 PROs, including
original development references, stated intended contexts of use and
details about construction.
3.2. Quality analysis
Table 2 summarises PRO content development quality analyses.
Supplementary Table 1 provides information informing the quality
analysis (extracted from development papers). Table 3 summarises
findings across all 24 PROs, highlighting systematic shortcomings in
content development quality. Overall findings for each assessment cri-
terion are discussed below.
3.2.1. Concept of interest (COI)
Both COSMIN and FDA require clarity of the measurement concept.
Whilst the ULF PROs we reviewed usually documented a concept for
measurement, most concepts were loosely described, rather than clearly
specified. Therefore, most PROs (17/24) had an ‘adequate’ COI rating.
For instance, MAM-16 and MAM-36 (an expanded scale for general
rehabilitation populations) are described as “task oriented and patient-
centred tool(s) that measures manual ability for hand use.” Neither
define what is meant by “manual ability”, the specific aspects of
“manual ability” measured, nor types of tasks covered by “task or-
iented”. Similar shortcomings were identified across most measures.
Two PROs didn't define any COI (UEFI and MAL). One PRO (FLEX-SF)
had a broad ambiguous definition (“shoulder function”), hence was
rated “poor”. Finally, no PROs described a process of patient/expert
engagement [12] to define the scope of the COI, any literature searches
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Fig. 1. Flow diagram illustrating literature searches, inclusion/exclusion criteria and identification of 24 UL PRO measures.
1 https://www.cosmin.nl/wp-content/uploads/COSMIN-methodology-for-
content-validity-user-manual-v1.pdf. Note that we have reworded the 4-point
scale from the original documentation, although the scoring strategy remains
the same.
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3.2.2. Conceptual/theoretical framework
COSMIN guidelines state theoretical models should delimit the
concepts boundaries, show relationships between related concepts and
subscales, and reflect the current state of science across relevant dis-
ciplines. We identified no measures satisfying COSMIN criteria for a
robust conceptual framework for ULF. No studies provided complete
concepts (e.g. divided into relational domains/subdomains), nor used
well-documented systematic literature searches, citations of theoretical
papers or expert/patient qualitative input to build a conceptual model.
Around half the PROs (13/24) provided no conceptual framework.
Another 9 PROs had doubtful (i.e. ill-defined) conceptual frameworks.
Thirteen PROs cited definitions from the WHO International
Classification of Functioning, Disability and Health (ICF) [13] for
activity limitations, functioning, impairment and participant restric-
tions (Table 2). However, the ICF is a generic taxonomy of some
functions which does not specifically delimit disability in ULF, and the
publications we reviewed provided no evidence (or theory) that the ICF
was relevant to the specific concept/context being measured. Finally,
some measures citing the ICF (e.g. ABILHAND measures) used its de-
finitions to define the broad domain of measurement (e.g. impairment,
disability, participation restrictions) rather than to construct their
theoretical framework. Whilst Neuro-QOL development involved a de-
tailed process of identifying important diseases, “health-related quality
of life” domains, subdomains and items, there was no conceptual fra-
mework per se and no elaboration on the “Upper Extremity Function”
domain measured.
Table 2
Quality analysis of content development for 24 ULF-PROs.




[Q4] COU [Q5] Representative
Sample






ABILHAND +? - (ICF) - −? −? - - RMT/Statistical
ABILHAND-NMD +? - (ICF) -? −? - - - RMT/Statistical
ABILHAND-RA +? - (ICF) + −? - - - RMT/Statistical
ABILHAND-SSC +? - (ICF) + −? - - - RMT/Statistical
ABILHAND-Stroke +? - (ICF) + −? - - - Logical/Statistical
AMHFQ +? - +? +? - - - Statistical
AMSQ +? −? (ICF) +? −? −? - −-? Expert/Statistical
ARM-A + −? + + −? −? + Expert/Delphi
AUSCAN +? - +? +? +? + −? Logical/Statistical
CUE +? +? (ICF) +? +? - - - Statistical
DASH +? −? +? −? - - - Logical/Expert
Quick DASH +? −? +? - - - - Logical/Expert
FLEX-SF - - - +? - −? - RMT/Statistical
MAL - - - - - - - None
MAM-16 +? −? (ICF) −? −? - - - RMT/Statistical
MAM-36 +? −? (ICF) +? +? - - - RMT/Statistical
MAP-HAND +? −? (ICF) +? +? +? +? +? RMT/Statistical
MAS +? +? (ICF) +? +? - - - Expert/Unclear
MHQ −? −? - +? - - - Logical/Statistical
Neuro-QoL FM/UEF −? - +? −? −? −? −? RMT/IRT/Expert
Neuro-QoL SF −? - +? +? −? −? −? IRT/Expert
UEFI - - (ICF) +? −? −? - - Statistical/
Redundancy
UEFS +? - +? −? −? - - Logical
ULFI +? −? (ICF) - −? − - +? Redundancy/
Logical
Quality assignments are as follows: Good (+), Adequate (+?), Doubtful (−?), Poor/None (−). See Supplementary Table 1 for details. For the columns:
Q1, ‘COI’ (Concept of interest); was a well-defined concept of interest documented?
Q2, ‘Conceptual framework’; was the concept of interest underpinned by a conceptual framework? When appended by ‘ICF’, the conceptual framework cited the WHO
International Classification of Functioning, Disability and Health.
Q3, ‘Target population’; did the measure have a well-defined target population?
Q4, ‘COU’ (Context of use); was the measure developed for use in a well-defined context?
Q5, ‘Representative sample’; was the scale development work conducted in a sample representing the intended context of use?
Q6, ‘Qualitative Items’; was qualitative work was used to generate items?
Q6a, ‘Literature items’; were literature reviews used to generate items?
The final column, ‘Item reduction’, indicates the method used to reduce the number of items (if there was an item reduction stage). RMT = Rasch Measurement
Theory; IRT = Item Response Theory. See Supplementary Table 1 for details.
Table 3
Summary of quality analysis of content development for 24 ULF-PROs.
Quality rating Quality criteria assessed
[Q1] COI [Q2] Conceptual framework [Q3] Target population [Q4] COU [Q5] Representative sample [Q6] Qualitative items [Q6a] Literature items
Good (+) 1 (4.2%) 0 (0%) 4 (16.7%) 1 (4.2%) 0 (0%) 1 (4.2%) 1 (4.2%)
Adequate (+?) 17 (70%) 2 (8.3%) 13 (54.2%) 9 (37.5%) 2 (8.3%) 1 (4.2%) 2 (8.3%)
Doubtful (−?) 3 (12.5%) 9 (37.5%) 2 (8.3%) 12 (50%) 7 (29.2%) 4 (16.7%) 4 (16.7%)
Poor/none (−) 3 (12.5%) 13 (54.2%) 5 (20.8%) 2 (8.3%) 15 (62.5%) 18 (75%) 17 (70.8%)
Each column is the number (percent) of sum of PROs scored for each of the seven quality criteria (see Table 1 and methods), according to the ratings. COI = concept
of interest; COU = context of use.
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3.2.3. Target population
Updated COSMIN standards recommend developers provide a clear
description of the target population for which the PRO was developed.
Seventeen PRO development papers specified target populations
achieving “good” (4/24; well-defined clinical population) or “ade-
quate” (13/24; loosely defined clinical population) ratings. Five PROs
didn't specify target populations (ABILHAND, FLEX-SF, MAL, MHQ,
ULFI).
One PRO, Arm Function in Multiple Sclerosis Questionnaire
(AMSQ), was developed specifically for people with MS (Table 1).
Another 12 PROs had broad concepts that might encompass MS (e.g.
neuromuscular disorders and general functioning: ABILHAND-NMD,
DASH, Quick DASH, MAL, MAM-16, MAM-36, MAS, Neuro-QoL, Neuro-
QoL-SF, UEFI, UEFS, ULFI). Ten PROs had non-MS contexts (e.g. spe-
cific to rheumatoid arthritis, stroke etc.: ABILHAND, ABILHAND-RA,
ABLIHAND-SSC, ABILHAND-Stroke, AMHFQ, ARM-A, AUSCAN, CUE,
MAP-HAND, MHQ).
3.2.4. Context of use (COU)
Updated COSMIN standards define context of use as the intended
application of the PROM. This was only well specified with one measure
(ARM-A). Contexts of use for half the PROs were poor/missing (2/24)
or doubtful (12/24). Most measures stated that the context of use is to
measure the concept of interest for clinical use on patients within the
intended population. Thus, whilst clinical targets were frequently cited,
the specific clinical purpose, context and samples (e.g. trial; acute care;
therapy etc.) were rarely defined (e.g. outcome assessment may require
a different instrument to a diagnostic tool). Whether a PRO was de-
veloped for discriminative, evaluative or predictive applications was
rarely stated. These contextual factors are required (by some) to de-
termine desirable properties of the final instrument. For example,
evaluative applications need to include items covering entire range of
the scale, whereas with diagnostic applications this may not be neces-
sary [5,9].
3.2.5. Representative sample
COSMIN and FDA recommend items for PROs are generated from
samples representative of the context in which the PRO will be used.
Two of 24 PROs (AUSCAN; MAP-HAND) generated items from well-
described target populations, although the sample representativeness
was only deemed COSMIN ‘adequate’. Whilst other instruments used
representative samples for psychometric evaluations, they did not de-
velop items using representative, diverse samples of the target clinical
population. Typically, samples used for item development were ex-
tremely limited/absent (15/24 PROs), or doubtful (7/24 PROs) – where
either the sample did not adequately represent the target population, or
the sample was not well described.
These shortcomings stemmed from broad definitions for ‘target
population’. For example, ARM-A targeted ‘hemiparetic upper limb
patients’, but items were generated from a small sample (n = 13) of
questionable representativeness (all were stroke patients, and authors
admitted sample was limited). Similarly, ABILHAND targeted people
with rheumatoid arthritis (RhA), using a convenience sample of n = 18
people with RhA who had hand surgery up to 25 yrs. ago and from
other” selected scales” (no further details given). Whilst development
papers often described the samples used for psychometric validation,
samples used for item generation did not often provide sample char-
acteristics (CUE, FLEX-SF, MAS, MHQ, NeuroQol, NeuroQoL SF, UEFI,
UEFS), and therefore the adequacy of the sample could not be assessed.
3.2.6. Qualitative work to generate items
COSMIN and FDA require clarity of the item generation processes.
One PRO (AUSCAN) documented well conducted qualitative methods
against a representative sample of patients (n = 50) across all instru-
ment domains, along with assurances that item saturation was reached
(i.e. no further items – or relevant themes – were uncovered in the final
set of qualitative interviews). Another PRO (MAP-HAND) used methods
deemed ‘adequate,’ with suitably documented qualitative methods (60
semi-structured interviews; video observations). However, the pub-
lication didn't clarify the representativeness of sample, level of satura-
tion reached, and which items were derived from qualitative work. Item
generation for many instruments (18/24) used either no qualitative
work or undocumented methods.
3.2.7. Literature review to generate items
One PRO (ARM-A) was developed using well-specified literature
searches, based on a previous systematic review. Two PROs (MAP-
HAND, ULFI) were rated ‘adequate’, with detailed literature performed
to generate items, but exact methods were not specified. Most PRO
development publications (17/24) did not conduct document literature
searches to generate items. Instead, they cited a small number of pre-
existing scales, without documenting how they were identified.
3.2.8. Item reduction / selection for final instrument
Most PROs contain less items than originally examined (sometimes
referred to as the item pool). Table 2 (final column) and Supplementary
Table 1 show a range of approaches used to reduce or select items from
original pool. This included exclusively statistical approaches (Rasch
Measurement (e.g. ABILHAND, MAP-HAND, Item Response (e.g. Neuro-
QoL) and Classical Test Theory criteria (e.g. AMHFQ) [RMT, IRT, CTT])
with items removed if (for example) they did not “fit” the requirements
of a statistic model, were redundant, had malfunctioning response ca-
tegories, were too easy or uncommon, unable to discriminate or missing
values> 10%.
Some PROs (Arm-A, DASH, MAS) used purely qualitative methods.
This included patient and caregiver interviews to reduce items by (for
example), identifying irrelevant items. Other PROs (e.g. Quick DASH)
used a concept-retention approach: selecting the highest ranking item/s
from each domain and concept. Some PROs (e.g. DASH) relied purely
on expert opinion (i.e. clinicians or researchers) for item reduction.
Only one PRO (Neuro-QoL) used a combination of qualitative work
with patients (the only instrument using cognitive interviews), expert
input and statistical judgement for item reduction. Several PROs
(AMHFQ, CUE, MAL, MAS) did not provide clear explanations of their
item reduction methods.
3.2.9. Miscellaneous issues
Our review highlighted other issues relevant to quality evaluation.
Whilst some might consider these minor omissions, they contribute to
an overall lack of measurement clarity and transparency, which is re-
quired by investigators from PROs used in high-stakes clinical trials. For
example, ARM-A had an undocumented additional item added after
psychometric testing. ABILHAND items originally had 4 response ca-
tegories, reduced to 3 without clarification (then propagated across
ABILHAND-derived PROs: ABILHAND-NMD, ABILHAND-RA, ABILH-
AND-SSC, ABILHAND-Stroke). For these ABILHAND-derived measures,
the number of initial items was 56, rather than 57 documented in the
original ABILHAND. How CUE and MAL scores are generated is unclear.
Two PROs had no (AUSCAN) or unclear (CUE) instructions for handling
missing data. Twelve PROs (ABILHAND, ABILHAND-NMD, ABILH-
AND-RA, ABILHAND-SSC, ABILHAND-Stroke, FLEX-SF, MAL, MAL-16,
MAL-36, Neuro-QoL, Neuro-QoL SF, UEFS), defined no recall period,
increasing ambiguity and reducing measurement accuracy.
4. Discussion
We aimed to identify all existing ULF PROs and determine their
suitability for MS clinical trials. None of 24 PROs satisfied COSMIN or
FDA criteria as fit-for-purpose measures in any clinical trials. Whilst
many of the PROs may be considered (by some) acceptable for low-
stakes exploratory studies, they do not satisfy criteria for registrational
or high-stakes clinical trials [14,15]. When suboptimal PROs are used,
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it is impossible to determine the extent to which they provide accurate
and clinically interpretable quantifications of ULF and of treatment
effects. Type II error (failing to detect a true effect or treatment impact
underestimation) of an unknown degree is the most likely outcome,
unless fit-for-purpose PROs are used. With no adequate ULF PROs, this
problem will continue to handicap outcomes of high-stakes clinical
trials.
Not surprisingly, COSMIN's recently revised PRO content develop-
ment checklist hasn't yet been used widely. Nevertheless, two pub-
lications using the standards have concluded PRO content validity is
“worrisome” [10,11]. Our review mirrors these findings. In particular,
instrument development was consistently weak with regard to patient
engagement, literature review and expert input to develop a targeted
concept of interest for measurement [15]. In the final publications,
attention was rarely given to conceptual frameworks (often absent),
contexts of use (often loosely defined), use of representative samples to
generate items (often no sample), use of qualitative work to generate
items (often not performed) and literature searches to generate items
(rarely documented).
All these criteria are essential for fit-for-purpose PRO measurement
(see, for example, the FDA Roadmap to patient-focused outcome mea-
surement in Clinical Trials – Fig. 2). Regularly used clinical concepts
like upper limb function, physical function, disability, wellbeing and
quality of life are broad, ambiguous umbrella terms. In trials they are
measured indirectly as a score derived from peoples' responses to a set
of questions (items), and for any item set to measure a concept accu-
rately, that concept must be clearly defined (to the extent possible), and
conceptualized so that the relationship between the score, items and
concept is transparent. Moreover, concepts may be context specific. For
example, “upper limb function” may be disease dependent (MS v stroke
v RhA), or differ across disease subtypes (relapsing v secondary pro-
gressive v primary progressive MS). These are empiric questions for
examination, determination and clarification, and cannot be assumed.
Consequently, if PRO developers wish to satisfy scientific and reg-
ulatory criteria, and trialists wish to use fit-for-purpose PROs, devel-
opers must define exactly what they seek to measure and the intended
context in which the PRO is used. It follows logically that conceptual
work and qualitative research should be undertaken in clearly defined
samples representing the intended context of use.
Multiple factors may have driven this widespread neglect of con-
cepts and contexts in PRO development. Health measurement evolved
from educational measurement and ability testing, where concept and
context issues may be less complicated (e.g. maths tests for children).
Standard psychometric textbooks predominantly concern statistical
methods with minimal sections on “content validity”, with typically
nothing devoted to defining and conceptualizing variables for mea-
surement [16–19]. Hence, there is limited guidance for PRO developers.
Finally, there has been circular thinking, where clinical concepts are
“defined” by the items used in the absence of underpinning conceptual
work.
Fig. 2. Roadmap to patient-focused outcome measurement in clinical trials, FDA 2013.
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Our review also highlights an over reliance and over interpretation
of statistical tests in concluding PRO validity. For example, correlations
with other measures and variables, known group differences validity
and hypothesis testing do not, despite claims, indicate what is being
measured, nor the quality with which a construct is being measured
[20–22].
Many scales have an item reduction stage in their development.
Typically, an item set is administered to a sample, response data ana-
lysed and items failing statistical criteria discarded. The advantage of
this approach is that binary applications of statistical criteria is easy.
The disadvantage is that results are sample-specific. This can lead to
different PROs from the same pool in different diseases. We think it
more correct when psychometric statistics are used as hypothesis tests.
Specifically, when PROs have strong conceptual bases the PRO is a
hypothesis of how a variable might be measured. Testing PRO data
against statistical tests identifies discrepancies from statistical require-
ments and indicate (diagnose) issues in the hypothesis for investigation
[23]. In this regard Rasch measurement theory (RMT), as articulated by
Andrich and Rasch, is the most advantageous statistical method as it
articulates, mathematically, requirements for measurement from PROs
[24].
Our study has limitations. Our searches were only performed up
until November 2017, and due to difficulties comprehensively identi-
fying all PRO development papers with systematic literature searches,
our review may be incomplete. Furthermore, we only evaluated ori-
ginal validation papers. According to FDA guidance,2 construct validity
could, in theory, be established post-hoc. However, his has not been
done for the 24 PROs identified to our knowledge, and certainly not in
MS. We only assessed the content development of original PRO refer-
ences for the first six items of the revised COSMIN checklist as these are
a pre-requisite for subsequent psychometric evaluations. Indeed,
COMSIN's guidance is that unless an adequate target population is in-
volved in PRO development the overall development is deemed “in-
adequate”. Similarly, COSMIN's protocol uses a ‘worst score counts’
method, because poor study methodological aspects aren't overcome by
sound psychometric profiles [10,11]. This view mirrors FDA's stance
that other types of validity or reliability testing will not overcome
problems with content validity. Due to the systematic shortcomings
across all ULF PROs, examining further psychometric evaluations was
deemed redundant, and therefore beyond the scope of this study.
MS clinical trials must use fit for purpose ULF PROs to ensure results
accurately reflect treatment effects; failure to do so will have damaging
implications for people with MS, health care funders, and sponsors by
undermining treatment development and licensing. Specifically, re-
search is required to define and conceptualise ULF in MS, identify im-
portant ULF concepts for measurement, articulate those concepts as
cohesive item sets, and determine empirically whether and how they
differ across MS types. This work is required to determine the suitability
of existing PROs, in addition to providing solid conceptual foundations
for a next generation of fit-for-purpose PROs. Without this work, MS
trials measuring ULF will have type II error of unquantifiable magni-
tude. The current state of play is indeed “worrisome” [10,11].
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